产品名称
Transglutaminase 2 Inhibitor, ZDON, A cell-permeable, peptide-based, irreversible inhibitor of transglutaminase 2 (TG2; IC50 = 150 nM for recombinant TG2). Reacts with the active site cysteine of TG2.
assay
≥98% (HPLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
off-white
solubility
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
Quality Level
Disclaimer
Toxicity: Standard Handling (A)
General description
A cell-permeable, peptide-based (Z- QVPL) irreversible inhibitor of transglutaminase 2 (TG2) (IC50 = 150 nM for recombinant TG2) that acts by reacting with the active site cysteine of TG2. Exhibits far less potency against TG1 and TG3. Shown to significantly increase PGC-1a and cytochrome c mRNA levels in Q7 and Q111 cells (~50 mM). Also shown to enhance cytochrome c promoter activity by 250% in Q111 cells. Exhibits protective effect in cells exposed to 3-nitropropionic acid and NMDA, however, it does not directly affect mitochondrial bioenergetics.
Other Notes
McConoughey, S. J., et al. 2010. EMBO Mol. Medicine.2, 349.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Min-Su Han et al.
Scientific reports, 10(1), 13228-13228 (2020-08-09)
Transglutaminase 2 (TG2), also known as tissue transglutaminase, is a calcium-dependent enzyme that has a variety of intracellular and extracellular substrates. TG2 not only increases in osteoarthritis (OA) tissue but also affects the progression of OA. However, it is still
Manuel Lisetto et al.
International journal of molecular sciences, 24(15) (2023-08-12)
Transglutaminase 2 (TG2) is a multifunctional protein widely distributed in various tissues and involved in many physiological and pathological processes. However, its actual role in biological processes is often controversial as TG2 shows different effects in these processes depending on
Anurag Rathore et al.
Scientific reports, 10(1), 5350-5350 (2020-03-27)
The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a genome-wide functional knockout screen using CRISPR-Cas9 in a HIV-1 latency cell line
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持